Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.

Overview
Date Founded

2014

Headquarters

45 Wiggins Avenue,Bedford, MA 01730

Type of Company

Public

Industries

Biotechnology

Company Description

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Contact Data
Trying to get in touch with decision makers at Stoke Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & Director

Co-Founder

Chief Financial & Accounting Officer

Chief Operating & Business Officer

Chief Medical Officer

Vice President, Head of Clinical Operations

Vice President, Head of Chemistry

Executive Vice President, Head of Research & Preclinical Development

Vice President, Head of Corporate Affairs

Senior Vice President of Regulatory Affairs & Quality

Board of Directors

Founder at Apple Tree Partners

Chief Executive Officer & Director at Stoke Therapeutics, Inc.

Diplomat at American Board of Toxicology

Partner at Apple Tree Partners

Site Controller-Meeth at Lenox Hill Hospital

President & Chief Executive Officer at Homology Medicines, Inc.

Co-Founder & Director at Stoke Therapeutics, Inc.

Paths to Stoke Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Stoke Therapeutics, Inc.
Owners & Shareholders
Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Details Hidden

Our firm was founded to help small investors build significant capital over time. Since we believe in owning as many promising stocks as possible, we generally buy on margin.* Borrowing to invest can force liquidations if the market collapses, so we try to balance this exposure by selling short. This ability to seek investments both up and downstream is rarely available to smaller investors. We, however, view it as an effective tool that doubles our clients' dollars at work (it also doubles our commissions), while moderately reducing their exposure to abrupt swings in the market. Our approach is not for the short-term investor. Clients must be able and willing to accept risks. Accounts will experience sharp fluctuations month to month, year to year. It takes a strong stomach to invest with us. Clients entrust decision making for their accounts to us: we buy and sell without asking our clients to authorize in advance each transaction. We are paid commissions for our work

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund's investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in \"crossover\" (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant's or their affiliates' proprietary capital.

Recent Transactions
Details Hidden

Stoke Therapeutics, Inc. issued USD Common Stock

Details Hidden

Stoke Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Associate

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onStoke Therapeutics, Inc. issued USD Common Stock

Key Stats and Financials As of 2018
Market Capitalization
$1.04B
Total Enterprise Value
Earnings Per Share
$-0.38
Revenue
$0
Net Profit
$-12.5M
EBITDA
$-12.6M
Total Debt
$0
Total Equity
$105M
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

SFML is a hands-on manager which aims to maximize returns and preserve capital for clients by primarily investing in listed Israeli companies to create a well-balanced, long-term portfolio.The firm takes a conservative approach to market exposure and leverage, managing risk by implementing a disciplined trading approach, using stop-losses and defined price targets for individual positions. They seek to reduce market risk by using correlated derivatives, shorting market indices, sector ETFs, or specific industry stocks with similar drivers and aim to neutralize currency risk by hedging all non-dollar denominated investments in their portfolio.

Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Suppliers
University of Southampton Computer Software | Southampton, SH

Southampton Engineering is a Construction company located in 30 Flying Goose Path, Water Mill, New York, United States.

Cold Spring Harbor Laboratory Medical Support Services | Cold Spring Harbor, NY

Cold Spring Harbor Laboratory, Inc. provides research services. It operates educational institutions. The firm offers research in cancer, neurobiology, plant genetics, and bioinformatics. It also offers laboratory workshops to science teachers, students, and other groups across the nation. The company was founded in 1890 and is headquartered in Cold Spring Harbor, NY.

Competitors
GW Pharmaceuticals Plc Pharmaceuticals - Cambridge, CA

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stoke Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stoke Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Stoke Therapeutics, Inc..